A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

September 16, 2022

Study Completion Date

February 13, 2025

Conditions
Relapsed or Refractory Solid Tumors
Interventions
DRUG

Lenvatinib

Lenvatinib capsules administered orally at 14 mg/m\^2 QD

Trial Locations (49)

1023

Starship Childrens Hospital ( Site 0826), Auckland

1094

Semmelweis University ( Site 0675), Budapest

2013

Wits Clinical Research ( Site 0579), Soweto

2031

Sydney Children's Hospital ( Site 0801), Randwick

3052

Royal Childrens Hospital Melbourne ( Site 0802), Parkville

3526

Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 0678), Miskolc

4032

Debreceni Egyetem Klinikai Kozpont ( Site 0677), Debrecen

4101

Queensland Children s Hospital ( Site 0804), Brisbane

6009

Perth Children s Hospital ( Site 0803), Nedlands

7505

Tygerberg Hospital ( Site 0578), Parow

7700

Cancercare Rondebosch Oncology ( Site 0575), Cape Town

9000

UZ Gent ( Site 0250), Ghent

10000

Klinika za djecje bolesti Zagreb ( Site 0725), Zagreb

10126

Ospedale Infantile Regina Margherita ( Site 0412), Torino

11000

Institute for Oncology and Radiology of Serbia ( Site 0780), Belgrade

Univerzitetska decja klinika ( Site 0782), Belgrade

13005

Hopital La Timone ( Site 0328), Marseille

15073

Clinica Anglo Americana ( Site 0203), San Isidro

16147

Istituto Giannina Gaslini ( Site 0411), Genova

20133

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0401), Milan

28009

Hospital Nino Jesus ( Site 0477), Madrid

34093

Istanbul Universitesi Onkoloji Enstitusu ( Site 0600), Istanbul

35040

Ege Universitesi Tip Fakultesi ( Site 0601), Izmir

35330

Dokuz Eylul Universitesi Arastirma Uygulama Hastanesi ( Site 0602), Izmir

37232

Monroe Carell Jr. Children's Hospital at Vanderbilt ( Site 0102), Nashville

44195

Cleveland Clinic ( Site 0119), Cleveland

50139

A.O.Universitaria Meyer-Oncology & Haematology Unit ( Site 0400), Florence

51000

Klinicki bolnicki centar Rijeka ( Site 0726), Rijeka

69008

Centre Leon-Berard ( Site 0326), Lyon

75005

Institut Curie ( Site 0325), Paris

75230

Mary Crowley Cancer Research Center ( Site 0107), Dallas

80045

Children's Hospital of Colorado ( Site 0110), Aurora

94800

Gustave Roussy ( Site 0327), Villejuif

117198

Dmitry Rogachev National Research Center ( Site 0550), Moscow

197022

St.Petersburg State Medical Univ. n.a. acad. I.P.Pavlov ( Site 0554), Saint Petersburg

197758

Clinical Research Center of specialized types medical care-Oncology ( Site 0553), Saint Petersburg

5265601

Chaim Sheba Medical Center ( Site 0500), Ramat Gan

B1629ODT

Hospital Universitario Austral ( Site 0126), Pilar

C1425EFD

Hospital de Niños Ricardo Gutiérrez ( Site 0125), Buenos Aires

613 00

Fakultni Nemocnice Brno Bohunice ( Site 0651), Brno

150 06

Fakultni nemocnice v Motole ( Site 0650), Prague

01011

Unidad Nacional de Oncologia Pediatrica ( Site 0176), Guatemala City

01016

Medi-K Cayala ( Site 0177), Guatemala City

00165

IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0410), Rome

05505

Asan Medical Center ( Site 0876), Songpagu

03080

Seoul National University Hospital ( Site 0875), Seoul

08950

Hospital Universitario Sant Joan de Deu ( Site 0476), Esplugues de Llobregat

221 85

Skanes Universitetssjukhus Lund. ( Site 0525), Lund

06100

Hacettepe Universitesi Tip Fakultesi ( Site 0603), Ankara

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04447755 - A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) | Biotech Hunter | Biotech Hunter